Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis
Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosisInterleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis, Published online: 14 February 2018; doi:10.1038/s41419-018-0288-4Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis
Bruna De Felice, Francesco Manfellotto, Giuseppe Fiorentino, Anna Annunziata, Elio Biffali, Raimondo Pannone, Antonio Federico
To the Editor We read with great interest the article by Rosenbohm and colleagues. They conducted a case-control study and reported that retinol-binding protein 4 had an inverse association with both risk for amyotrophic lateral sclerosis (ALS) and disease prognosis. Although we agree with the relevance of the reported results and their interpretation, we would like to comment on 2 issues that might also correlate with these findings.
In Reply We appreciate the comments of Riancho et al on our article investigating the association of retinol-binding protein 4 (RBP4) concentrations with the amyotrophic lateral sclerosis (ALS) risk and prognosis in the ALS registry Swabia. In their letter, they pointed out important clinical aspects and suggested that the causes of the disease could vary depending on the clinical characteristics of ALS and should be considered.
Amyotrophic lateral sclerosis (ALS), the most common degenerative disease affecting motor neurons, lacks an effective disease-modifying disease treatment [1 –3]. Recently, the Src/c-Abl pathway has been postulated as a potential therapeutic target in ALS. . Imamura et al. developed a phenotypic screen to repurpose existing drugs for ALS patients, which resulted in the identification of 27 potential hits. Intriguingly, more than half of the hits tar geted the Src/c-Abl signaling pathway . Complementary studies demonstrated that Src/c-Abl inhibitors increased the survival of induced pluripotent stem cells (iPSC)-...
Condition: Amyotrophic Lateral Sclerosis Interventions: Drug: BIIB078; Drug: Placebo Sponsor: Biogen Not yet recruiting
We compared the functioning of two neurological patient groups, amyotrophic lateral sclerosis (ALS) and traumatic brain injury (TBI), using brief and validated International Classification of Functioning (ICF)-based tools. A 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0) questionnaire was mailed to ALS and TBI patients and their significant others 2 weeks before their appointment at an outpatient clinic of a university hospital. In addition, a neurologist filled in the ICF minimal generic set. Two years after diagnosis, no significant differences between the two diagnosis groups were found in...
ConclusionIntegrated PET-MR imaging demonstrates associations between markers for neuronal integrity and neuroinflammation and may provide valuable insights into disease mechanisms in ALS.
Chemical ReviewsDOI: 10.1021/acs.chemrev.8b00138
AbstractMany central nervous system diseases currently lack effective treatment and are often associated with defects in microvascular function, including a failure to match the energy supplied by the blood to the energy used on neuronal computation, or a breakdown of the blood–brain barrier. Pericytes, an u nder-studied cell type located on capillaries, are of crucial importance in regulating diverse microvascular functions, such as angiogenesis, the blood–brain barrier, capillary blood flow and the movement of immune cells into the brain. They also form part of the “glial” scar isolating dam...
Conclusions: Federal healthcare claims databases ascertained are a very efficient method for identifying the majority of ALS-prevalent cases in the National ALS Registry, and may be enhanced by having patients self-register through the registry web portal.Neuroepidemiology 2018;51:149 –157